Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
We discuss updated results from the BRUIN study, a phase 1/2 clinical trial of pirtobrutinib in patients with advanced B-cell malignancies, including CLL, who have received >2 prior therapies.
The purpose of this article is to share how to maintain a positive attitude through a cancer journey. Understand, this is one patient’s perspective. Having been an athlete my whole life, I realize the power of the mind. While I’m not able to change what’s happening to me inside my body, how I think about it has an impact.
We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.
Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)
We discussed an analysis of acquired mutations in patients from the MURANO trial whose disease had progressed.
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous illness with a variable clinical course primarily determined by the disease’s underlying genetics, which is not the same for each affected individual. However, one gene that is highly important in predicting the natural history of CLL and response to chemoimmunotherapy is TP53, which resides on chromosome 17.
Four world-class CLL physicians reviewed the latest research and offered case study examples to illustrate their new approaches to treating CLL. The panel, sponsored by the Peer Review Institute and the CLL Society, was for medical professionals and is quite comprehensive in terms of clinical trial data as well as real-world insights from surveys, etc.
Discussion of outcomes for patients with del(17p) or TP53 mutations who have been treated with first-line BTK inhibitors such as ibrutinib or acalabrutinib.
Chairman of the Board and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the final results of a phase 1/2 clinical trial of entospletinib combined with obinutuzumab in patients with relapsed/refractory CLL.
One click to our most popular content.
